Stoke Therapeutics, Inc. (STOK) NASDAQ
28.68
-1.79(-5.87%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Stoke Therapeutics, Inc.
Address
45 Wiggins Avenue
Bedford, MA 01730
United States of America (the)
Phone
781 430 8200
Sector
Healthcare
Industry
Biotechnology
Employees
128
First IPO Date
June 19, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Ian F. Smith | Chief Executive Officer & Director | 1.41M | 1966 |
| Adrian R. Krainer | Co-Founder & Independent Director | 45,000 | 1959 |
| Barry S. Ticho FACC | Chief Medical Officer | 726,501 | 1961 |
| Edward Kaye | Advisor & Director | 736,384 | 1949 |
| Thomas Edward Leggett | Chief Financial Officer | 804,024 | 1977 |
| Jason Hoitt | Chief Patient Officer | 815,418 | 1978 |
| Isabel Aznarez | Co-Founder, Head of Research & Senior Vice President | 0 | 1973 |
| Doug Snow | Director of Communications & Investor Relations | 0 | N/A |
| Jonathan Allan | Corporate Secretary & General Counsel | 0 | 1990 |
| Dawn Kalmar | Chief of Corporate Affairs & Strategic Partnerships | 0 | 1977 |
| Sara Den Besten | Chief People Officer | 0 | N/A |
| Susan Willson | Vice President of Corporate Communications | 0 | N/A |
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
